Sumagen’s World First Killed Whole HIV Vaccine Set For Phase II
Executive Summary
After a positive outcome from a US Phase I study, South Korea's Sumagen is stepping closer to the launch of the world's first killed-whole HIV vaccine with potential to both prevent and treat AIDS.
You may also be interested in...
Janssen Strives For Simplicity In HIV R&D, While Hunting For A Cure
HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.